Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982571 | 0.99 | NAAA (0.39) | NAAAPTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL4987231 | 0.99 | NAAA (0.39) | NAAAPTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL4186784 | 0.88 | NAAA (0.39) | NAAAPTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL4184504 | 0.79 | OPRM1 (0.33) | NAAAPTGDR2OPRM1OPRK1 | |
| SCHEMBL4977956 | 0.77 | OPRM1 (0.34) | NAAAPTGDR2OPRM1OPRK1 | |
| SCHEMBL1999955 | 0.76 | SLC6A2 (0.40) | NAAAPTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL20476348 | 0.76 | KDM4E (0.41) | NAAAPTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL4985782 | 0.76 | OPRM1 (0.33) | NAAAPTGDR2KDM4EALDH1A1HPGD | |
| SCHEMBL4190993 | 0.75 | GRIN2B (0.39) | ALDH1A1 | |
| SCHEMBL4193805 | 0.74 | GRIN2B (0.38) | PTGDR2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | claimed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | claimed |
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | US | disclosed |
| EP-1968980-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007110782-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137623-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM5 | NAAA 2588/4885PTGDR2 111/4885KDM4E 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.